.jpg)
SEPT6-ABL2 fusion for use in the diagnosis and/or treatment of cancer
Patent number:
PCT/EP2022/065750; EP21382663
No items found.
The present invention refers to a cell line characterized by comprising the fusion gene [SEPT6-ABL2] within its genetic material, or the fusion transcript [SEPT6-ABL2], and also to the use of [SEPT6-ABL2] fusion in a method for the diagnosis and/or treatment of cancer.
Countries:
Spain
Regions:
Community of Madrid
Centers:
UNIVERSIDAD AUTONOMA DE MADRID, FUNDACION INSTITUTO DE INVESTI GACION SANITARIA FUNDACION JIMENEZ DIAZ
Other entities:
Sectors:
Health
Subsectors:
TRL Level:
TRL 5 – technology validated in relevant environment (industrially relevant environment in the case of key enabling technologies)
BRL Level:
PDF Link:
Download hereVideo Link:
Watch it hereSustainable Development Goal:
SDG03: Good health and well-being
Applications
The present invention refers to the medical field. Particularly, the present invention refers to a cell line characterized by comprising the fusion gene [SEPT6-ABL2] within its genetic material, or the fusion transcript [SEPT6-ABL2]. The present invention is also focused on the use of SEPT6-ABL2 fusion in a method for the diagnosis and/or treatment of cancer.
Comments